Home/Pipeline/SPU-16

SPU-16

Multiple Sclerosis

PreclinicalResearch

Key Facts

Indication

Multiple Sclerosis

Phase

Preclinical

Status

Research

Company

Silo Pharma

About Silo Pharma

Silo Pharma is a Nasdaq-listed biotech focused on developing novel therapeutics for central nervous system disorders and chronic pain through a capital-efficient licensing and development model. Its core strategy involves in-licensing promising candidates from academic partners and advancing them via the FDA's 505(b)(2) regulatory pathway to reduce time and cost. Key assets include SPC-15, a prophylactic intranasal treatment for stress-induced disorders, and SP-26, a ketamine-based implant for fibromyalgia. The company aims to address significant unmet medical needs in large, growing markets with limited treatment options.

View full company profile

Therapeutic Areas

Central Nervous System Psychiatry Chronic Pain

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
Evobrutinib	EMD Serono	Phase 3	Active